The liquid biopsy market in the UAE is expected to reach a projected revenue of US$ 37.3 million by 2033. A compound annual growth rate of 9.5% is expected of the UAE liquid biopsy market from 2026 to 2033.
In terms of revenue, UAE accounted for 0.1% of the global liquid biopsy market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Middle East & Africa, Saudi Arabia liquid biopsy market is projected to lead the regional market in terms of revenue in 2033.
UAE is the fastest growing regional market in Middle East & Africa and is projected to reach USD 37.3 million by 2033.
Several strategic initiatives have been undertaken in the country. In April 2022, Viafet Genomics Laboratory collaborated with Euformatics to provide carrier screening and clinical diagnostics in the UAE.
Illumina's recent NGS and array technologies are over the 9,100- square-foot solutions center. Numerous clinical applications, including oncology, genetic disease testing, noninvasive prenatal testing, and quick diagnostic testing, can be performed with the equipment.
Moreover, the UAE is one of the leading contributors to the cancer burden in the MEA. According to UAE National Cancer Registry, in 2019, the country reported over 4,633 new cancer cases, of which 4,381 were malignant and 252 were in situ.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Liquid Biopsy Market Outlook will help companies and investors design strategic landscapes.
Blood Sample Based was the largest segment with a revenue share of 80.0% in 2025.
Horizon Databook has segmented the Uae liquid biopsy market based on blood sample based covering the revenue growth of each sub-segment from 2021 to 2033.
Several strategic initiatives have been undertaken in the country. In April 2022, Viafet Genomics Laboratory collaborated with Euformatics to provide carrier screening and clinical diagnostics in the UAE.
Illumina's recent NGS and array technologies are over the 9,100- square-foot solutions center. Numerous clinical applications, including oncology, genetic disease testing, noninvasive prenatal testing, and quick diagnostic testing, can be performed with the equipment.
Moreover, the UAE is one of the leading contributors to the cancer burden in the MEA. According to UAE National Cancer Registry, in 2019, the country reported over 4,633 new cancer cases, of which 4,381 were malignant and 252 were in situ.
Uae Liquid Biopsy Market Sample Type Outlook (Revenue, USD Million , 2021-2033)
Blood Sample Based
Others
Uae Liquid Biopsy Market Biomarker Outlook (Revenue, USD Million , 2021-2033)
Circulating Nucleic Acids
CTC
Exosomes/Microvesicles
Circulating Proteins
Uae Liquid Biopsy Market Technology Outlook (Revenue, USD Million , 2021-2033)
Multi-gene-parallel Analysis (NGS)
Single Gene Analysis (PCR Microarrays)
Uae Liquid Biopsy Market Application Outlook (Revenue, USD Million , 2021-2033)
Cancer
Reproductive Health
Others
Uae Liquid Biopsy Market End Use Outlook (Revenue, USD Million , 2021-2033)
Hospitals and Laboratories
Specialty Clinics
Academic and Research Centers
Others
Uae Liquid Biopsy Market Clinical Application Outlook (Revenue, USD Million , 2021-2033)
Therapy Selection
Treatment Monitoring
Early Cancer Screening
Recurrence Monitoring
Others
Uae Liquid Biopsy Market Product Outlook (Revenue, USD Million , 2021-2033)
Instruments
Consumables Kits and Reagents
Software and Services
Reasons to subscribe to Liquid Biopsy Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Liquid Biopsy Market Outlook databook
Our clientele includes a mix of Liquid Biopsy Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE Liquid Biopsy Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into UAE Liquid Biopsy Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.